Modality
mAb
MOA
USP1i
Target
AHR
Pathway
Angiogenesis
WilmsCeliacHeart Failure
Development Pipeline
Preclinical
~Sep 2020
→ ~Dec 2021
Phase 1
Mar 2022
→ Nov 2031
Phase 1Current
NCT04903634
2,559 pts·Celiac
2023-06→TBD·Completed
NCT04464178
512 pts·Celiac
2022-03→2031-11·Completed
3,071 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-11-055.6y awayPh2 Data· Celiac
Trial Timeline
2022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P1/2
Complet…
P1/2
Complet…
Catalysts
Ph2 Data
2031-11-05 · 5.6y away
Celiac
Completed|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04903634 | Phase 1/2 | Celiac | Completed | 2559 | Biomarker |
| NCT04464178 | Phase 1/2 | Celiac | Completed | 512 | PANSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2901 | Pfizer | Phase 2 | AHR | |
| AZN-1715 | AstraZeneca | Phase 3 | AHR | |
| SNY-2934 | Sanofi | Phase 3 | KRASG12D | |
| BAY-6520 | Bayer | Phase 2 | AHR | |
| AMG-9052 | Amgen | Phase 2/3 | CDK2 | |
| Datozumab | Regeneron | Phase 1 | B7-H3 | |
| GMA-729 | Genmab | Phase 2 | BCL-2 | |
| Semasacituzumab | Jazz Pharma | Phase 2 | AHR | |
| Pexanaritide | Innovent Bio | Preclinical | SGLT2 | |
| ROI-9675 | Roivant Sciences | NDA/BLA | HER2 |